Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cancer stem cells associated miRNAs serve as prognostic biomarkers in colorectal cancer

ABSTRACT: Cancer stem cells associated miRNAs serve as prognostic biomarkers in colorectal cancer

PROVIDER: PRJNA517925 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8507520.fastq.gz	Fastqsanger.gz
	SRR8507521.fastq.gz	Fastqsanger.gz
	SRR8507522.fastq.gz	Fastqsanger.gz
	SRR8507515.fastq.gz	Fastqsanger.gz
	SRR8507516.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Cancer stem cells associated miRNAs serve as prognostic biomarkers in colorectal cancer

Project description:Chemoresistance in cancer is linked to a subset of cancer cells termed “cancer stem cells” (CSCs), and in particular, those expressing the CD44 variant appear to represent a more aggressive disease phenotype. Herein, we demonstrate that CD44v6 represents a CSC population with increased resistance to chemotherapeutic agents, and its high expression is frequently associated with poor overall survival (OS) (HR:3.04; CI:1.35–6.85; p<0.001) and disease-free survival (DFS) (HR:5.30, CI:1.64–17.12, p<0.01) in CRC patients. CD44v6+ cells showed elevated resistance to chemotherapeutic drugs and significantly high tumor initiation capacity. The inhibition of CD44v6 resulted in the attenuation of self-renewal capacity and re-sensitization to chemotherapeutic agents. Of note, miRNA profiling of CD44v6+ SDCSCs identified a unique panel of miRNAs indicative of high self-renewal capacity. In particular, miR-1246 was overexpressed in CD44v6+ cells, and associated with poor OS (HR:2.44, CI:1.15–5.18, p<0.05) and DFS (HR:2.37, CI:1.03–5.44, p<0.05) in CRC patients. We demonstrate that CD44v6+ CSCs induced chemoresistance and enhance tumorigenicity in CRC cells, which is in part orchestrated by dysregulated profiles of a distinct panel of miRNAs. These findings provide a rationale for the therapeutic targeting of specific miRNAs, as well as serving as promising prognostic biomarkers in patients with colorectal neoplasia.

2019-02-22 | GSE125904 | GEO

EV-miRNAs as biomarkers of breast cancer recurrence

Project description:EV-miRNAs as biomarkers of breast cancer recurrence

| PRJNA992498 | ENA

Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer.

Project description:Chemoresistance in cancer is linked to a subset of cancer cells termed "cancer stem cells" (CSCs), and in particular, those expressing the CD44 variant appear to represent a more aggressive disease phenotype. Herein, we demonstrate that CD44v6 represents a CSC population with increased resistance to chemotherapeutic agents, and its high expression is frequently associated with poor overall survival (OS) and disease-free survival (DFS) in patients with colorectal cancer (CRC). CD44v6+ cells showed elevated resistance to chemotherapeutic drugs and significantly high tumor initiation capacity. Inhibition of CD44v6 resulted in the attenuation of self-renewal capacity and resensitization to chemotherapeutic agents. Of note, miRNA profiling of CD44v6+ spheroid-derived CSCs identified a unique panel of miRNAs indicative of high self-renewal capacity. In particular, miR-1246 was overexpressed in CD44v6+ cells, and associated with poor OS and DFS in CRC patients. We demonstrate that CD44v6+ CSCs induced chemoresistance and enhance tumorigenicity in CRC cells, and this was in part orchestrated by a distinct panel of miRNAs with dysregulated profiles. These findings suggest that specific miRNAs could serve as therapeutic targets as well as promising prognostic biomarkers in patients with colorectal neoplasia.

| S-EPMC6483002 | biostudies-literature

The miRNAs in plasma exosomes may serve as markers for segmental vitiligo

Project description:More and more studies have showed that plasma exosomal miRNAs are biomarkers for disease. The aim of the study were to investigate the miRNA profiling in plasma exosomes of patients with segmental vitiligo (SV) and to find biomarkers in plasma exosomes for patients with SV. Plasma exosomes and exosomal RNA of 7 SV patients and 8 health persons were purified by exoRNeasy Serum/Plasma Maxi Kit. The miRNA profiles of the 15 samples were sequenced using HiSeq 2500 (Illumina) and analyzed by Reads Per Million (RPM) values and edgeR algorithm. Some differently expressed miRNAs in plasma exosomes and skin tissues of the two sets were validated by qRT–PCR.A total of 85 miRNAs in plasma exosomes showed differential expression between SV patients and health persons, with a |log2（Fold Change）|≥1 and P-value < 0.05. Several miRNAs were confirmed by qRT–PCR and showed similar expression patterns between plasma exosomes and skin tissues. Our study depict the miRNAs expression profiles in plasma exosomes of SV patients and suggest that several miRNAs in plasma exosomes may serve as biomarkers for SV.

2022-03-24 | GSE198956 | GEO

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality

Project description:Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality

| PRJNA667048 | ENA

The miRNAs in plasma exosomes may serve as markers for non-segmental vitiligo

Project description:More and more studies have showed that plasma exosomal miRNAs are biomarkers for disease. The aim of the study were to investigate the miRNA profiling in plasma exosomes of patients with non-segmental vitiligo (NSV) and to find biomarkers in plasma exosomes for patients with NSV. Plasma exosomes and exosomal RNA of 10 NSV patients and 10 health persons were purified by exoRNeasy Serum/Plasma Maxi Kit. The miRNA profiles of the 20 samples were sequenced using HiSeq 2500 (Illumina) and analyzed by Reads Per Million (RPM) values and edgeR algorithm. Some differently expressed miRNAs in plasma exosomes and skin tissues of the two sets were validated by qRT–PCR.Several miRNAs were confirmed by qRT–PCR and showed similar expression patterns between plasma exosomes and skin tissues. Our study depict the miRNAs expression profiles in plasma exosomes of NSV patients and suggest that several miRNAs in plasma exosomes may serve as biomarkers for NSV.

2022-12-09 | GSE141655 | GEO

Prognostic biomarkers of antipsychotic-induced weight gain

Project description:Prognostic biomarkers of antipsychotic-induced weight gain

| PRJNA661304 | ENA

Plasma miRNAs as biomarkers of epilepsy

Project description:Plasma miRNAs as biomarkers of epilepsy

| PRJNA1009812 | ENA

Benchmarking pathway analysis methods offer novel prognostic cancer biomarkers and therapeutics: application in bladder cancer

Project description:Benchmarking pathway analysis methods offer novel prognostic cancer biomarkers and therapeutics: application in bladder cancer

| PRJNA922546 | ENA

Benchmarking pathway analysis methods offer novel prognostic cancer biomarkers and therapeutics: application in bladder cancer

Project description:The pathogenesis of cancer is typically driven by alterations in multiple cellular pathways that are challenging to identify and target. However, it is unclear how suitable the existing pathway analysis tools are for unbiased discovery and ranking of dysregulated and/or cancer-specific pathways. Here, we created a new platform called Benchmark to evaluate the potential of pathway analysis tools for discovery under experimental conditions. Unexpectedly, we found that despite wide-spread success in confirming hypothesized dysregulated pathways, common pathway analysis tools are less than ideal for unbiased discovery. Nevertheless, our pathway ensemble tool (PET) that combines the rank statistics from the exisiting methods significantly enhanced discovery. We applied PET to transcriptomics data from 12 independent tumor types to identify prognostic pathways. We showed that the genes from prognostic pathways are excellent biomarkers and can define cancer molecular subtypes. Moreover, drug prediction to normalize genes from prognostic pathways identified effective known and novel drugs. Finally, in vitro and/or a xenograft models of bladder cancer treated with the top predicted drug significantly restricted tumor cells. We anticipate that our unbiased approach for pathway discovery will have tangible impacts on cancer management.

2024-06-03 | GSE222567 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data